United Historical Balance Sheet
UTHR Stock | USD 276.44 1.25 0.45% |
Trend analysis of United Therapeutics balance sheet accounts such as Total Assets of 7.5 B, Short Long Term Debt Total of 735 M, Other Current Liabilities of 116.3 M or Total Current Liabilities of 844.6 M provides information on United Therapeutics' total assets, liabilities, and equity, which is the actual value of United Therapeutics to its prevalent stockholders. By breaking down trends over time using United Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining United Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether United Therapeutics is a good buy for the upcoming year.
United Therapeutics Inventory |
|
United |
About United Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of United Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. United Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of United Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which United currently owns. An asset can also be divided into two categories, current and non-current.
United Therapeutics Balance Sheet Chart
United Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how United Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, United Therapeutics' Accounts Payable is relatively stable compared to the past year. As of 05/22/2024, Cash is likely to grow to about 1.3 B, while Non Currrent Assets Other are likely to drop slightly above 91.5 M. Add Fundamental
Total Assets
Total assets refers to the total amount of United Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in United Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on United Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of United Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most accounts from United Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' Accounts Payable is relatively stable compared to the past year. As of 05/22/2024, Cash is likely to grow to about 1.3 B, while Non Currrent Assets Other are likely to drop slightly above 91.5 M.
2023 | 2024 (projected) | Short and Long Term Debt Total | 700M | 735M | Total Assets | 7.2B | 7.5B |
United Therapeutics balance sheet Correlations
Click cells to compare fundamentals
United Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
United Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Other Current Liab | 39.6M | 319.2M | 301.6M | 339.1M | 71M | 116.3M | |
Total Current Liabilities | 463M | 323.3M | 305.4M | 343.2M | 804.4M | 844.6M | |
Total Stockholder Equity | 2.8B | 3.4B | 4.0B | 4.8B | 6.0B | 6.3B | |
Property Plant And Equipment Net | 738.5M | 731.6M | 780.9M | 861.5M | 1.0B | 1.1B | |
Net Debt | 111.6M | 61.3M | (94.8M) | (161.2M) | (507.7M) | (482.3M) | |
Retained Earnings | 3.3B | 3.8B | 4.3B | 5.0B | 6.0B | 6.3B | |
Accounts Payable | 23.1M | 9.9M | 4.1M | 3.8M | 5.6M | 10.2M | |
Cash | 738.4M | 738.7M | 894.8M | 961.2M | 1.2B | 1.3B | |
Non Current Assets Total | 2.0B | 2.4B | 2.8B | 2.7B | 3.6B | 3.8B | |
Non Currrent Assets Other | 154.6M | 169.9M | 108.2M | 114.3M | 151.8M | 91.5M | |
Cash And Short Term Investments | 2.3B | 3.0B | 3.6B | 4.2B | 3.0B | 3.1B | |
Net Receivables | 151.4M | 157.4M | 198.7M | 220.4M | 278.9M | 292.8M | |
Common Stock Shares Outstanding | 43.8M | 44.6M | 47.3M | 48.5M | 49.7M | 50.7M | |
Liabilities And Stockholders Equity | 3.9B | 4.6B | 5.2B | 6.0B | 7.2B | 7.5B | |
Non Current Liabilities Total | 670M | 896.5M | 904.8M | 904.6M | 377.8M | 269.4M | |
Other Current Assets | 133.8M | 88.3M | 100.4M | 219.2M | 166.2M | 174.5M | |
Other Stockholder Equity | (531.3M) | (430.5M) | (333.8M) | (190.8M) | (30.2M) | (28.7M) | |
Total Liab | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B | |
Total Current Assets | 1.9B | 2.2B | 2.3B | 3.4B | 3.6B | 3.7B | |
Short Term Investments | 747.5M | 1.1B | 1.0B | 1.9B | 1.8B | 1.9B | |
Property Plant And Equipment Gross | 738.5M | 731M | 1.1B | 1.2B | 1.5B | 1.5B | |
Intangible Assets | 130.3M | 130.1M | 16.6M | 16.5M | 80.5M | 84.5M | |
Other Liab | 67M | 79.4M | 104.8M | 76.8M | 88.3M | 60.5M | |
Other Assets | 293.8M | 1.6B | 370.1M | 413.5M | 475.5M | 284.7M | |
Inventory | 93.4M | 86.5M | 93.8M | 102M | 111.8M | 55.9M | |
Property Plant Equipment | 738.5M | 731.6M | 780.9M | 861.5M | 990.7M | 1.0B | |
Net Tangible Assets | 2.6B | 3.2B | 3.9B | 4.8B | 5.5B | 5.7B | |
Retained Earnings Total Equity | 3.3B | 3.8B | 4.3B | 5.0B | 5.8B | 6.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.27 | Earnings Share 21.16 | Revenue Per Share 53.184 | Quarterly Revenue Growth 0.337 | Return On Assets 0.1225 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.